Polysomnography (Sleep Study): What Your Numbers Change About Your Treatment

What a Sleep Study Actually Measures

A polysomnography (PSG) is an overnight, in-lab recording that simultaneously tracks brain waves (EEG), eye movements (EOG), chin and leg muscle activity (EMG), heart rhythm (ECG), airflow, respiratory effort, and blood oxygen saturation. The test produces a multi-page report. Most patients only hear "you have sleep apnea" or "you don't," but the granular data inside that report influences far more than a CPAP prescription.

The Core Metrics in Your Report

The AHI counts full breathing stoppages (apneas) and partial obstructions (hypopneas) per hour. The American Academy of Sleep Medicine (AASM) classifies severity as mild (5 to 14), moderate (15 to 29), or severe (30+) [1]. The oxygen desaturation index (ODI) tallies how often SpO2 drops by 3% or more per hour. Your oxygen nadir is the lowest single SpO2 reading during the night.

Beyond Breathing: Sleep Architecture

The report also breaks your night into stages: N1 (light), N2, N3 (deep/slow-wave), and REM. The percentage of time spent in each stage, plus how often you cycle through them, is your sleep architecture. A healthy adult spends roughly 13 to 23% of total sleep time in N3 and 20 to 25% in REM [2]. Disrupted architecture shows up as reduced N3 or fragmented REM, both of which have downstream hormonal consequences.

How AHI Severity Drives First-Line Treatment Decisions

Your AHI score is the single most influential number on the report. It determines whether your clinician prescribes positive airway pressure, an oral appliance, a hypoglossal nerve stimulator, or watchful waiting. The AASM clinical practice guideline (2019) recommends CPAP as first-line therapy for moderate-to-severe OSA (AHI ≥15), while mild OSA (AHI 5 to 14) may be managed with an oral appliance if CPAP is declined [3].

Mild OSA: When Lifestyle Alone May Suffice

For patients with an AHI between 5 and 14 and no significant daytime sleepiness, weight loss of 10 to 15% body weight can reduce AHI by approximately 50%, based on data from the Sleep AHEAD study (N=264) [4]. If BMI is above 30, a GLP-1 receptor agonist prescribed for weight management may indirectly treat the apnea. The SURMOUNT-OSA trial (N=469) showed tirzepatide reduced AHI by 55.3% at 52 weeks in participants with moderate-to-severe OSA who were not using CPAP [5].

Moderate-to-Severe OSA: Device and Drug Implications

An AHI of 15 or higher typically triggers a CPAP prescription. But CPAP adherence hovers near 50% at one year [6]. For patients who cannot tolerate CPAP, the Inspire hypoglossal nerve stimulator is FDA-approved for AHI between 15 and 65 with a central apnea index below 25% [7]. Drug options remain limited: the FDA has not approved any pharmacotherapy specifically for OSA as of May 2026, though tirzepatide received expanded labeling for moderate-to-severe OSA with obesity in late 2024.

Oxygen Nadir and Desaturation Index: Cardiovascular Drug Adjustments

The oxygen nadir and ODI matter independently of AHI. A nadir below 80% SpO2 is associated with a 2.9-fold increase in incident hypertension, according to the Wisconsin Sleep Cohort data (N=709, 8-year follow-up) [8]. Clinicians treating a patient with repeated desaturations below 85% will often start or intensify antihypertensive therapy even before CPAP is established.

Blood Pressure Medication Selection

The Endocrine Society and the AHA/ACC guidelines note that resistant hypertension (blood pressure uncontrolled on three drugs) should prompt OSA screening [9]. CPAP itself lowers systolic blood pressure by a modest 2 to 3 mmHg on average, but the effect rises to 5+ mmHg in patients with severe nocturnal hypoxemia who use CPAP more than 4 hours per night [10]. Aldosterone antagonists like spironolactone show particular efficacy in hypertensive OSA patients because aldosterone excess contributes to both fluid retention in the pharynx and resistant hypertension [11].

Cardiovascular Risk Stratification

An ODI above 20 events per hour independently predicts atrial fibrillation risk (HR 2.18, 95% CI 1.34 to 3.54) in the Sleep Heart Health Study (N=6,441) [12]. Clinicians may lower the threshold for anticoagulation or choose rate-control agents more aggressively in patients whose sleep study reveals this pattern.

Sleep Architecture and Hormone Therapy

This is where the sleep study intersects directly with HealthRX's clinical focus areas. Growth hormone, testosterone, and cortisol secretion are all tightly linked to sleep stage distribution.

Testosterone and Sleep Apnea: A Two-Way Street

Testosterone replacement therapy (TRT) can worsen OSA. The Endocrine Society Clinical Practice Guideline (2018) lists untreated severe OSA as a relative contraindication to initiating TRT [13]. Practically, this means a man with hypogonadal symptoms and an AHI above 30 should treat the apnea before (or concurrently with) starting testosterone.

A prospective study by Hoyos et al. (N=67, 18 weeks) published in the Journal of Clinical Endocrinology & Metabolism found that intramuscular testosterone (1,000 mg undecanoate) worsened the ODI by 10.3 events/hour compared to placebo in obese men with severe OSA not on CPAP [14]. In contrast, men with mild-to-moderate OSA who are adherent to CPAP can generally initiate TRT safely with repeat PSG monitoring at 3 to 6 months.

HealthRX clinical decision framework for TRT and OSA:

| AHI Result | TRT Decision | |---|---| | AHI <5 (no OSA) | Initiate TRT per standard protocol | | AHI 5 to 14 (mild) | Initiate TRT; repeat PSG or home sleep test at 3 months | | AHI 15 to 29 (moderate) | Start CPAP first; initiate TRT once CPAP adherent (≥4 h/night) for 30 days; recheck PSG at 6 months | | AHI ≥30 (severe) | Treat OSA first; defer TRT until AHI confirmed below 30 on treatment; monitor closely |

Growth Hormone Secretion and N3 Sleep

Approximately 70% of daily growth hormone (GH) output occurs during N3 (slow-wave) sleep [15]. Patients whose PSG shows N3 below 10% of total sleep time may have blunted GH secretion. This matters for patients considering GH-releasing peptides (CJC-1295, ipamorelin) because maximizing deep sleep can amplify the peptide's effect. An editorial in Sleep Medicine Reviews noted that "pharmacologic GH augmentation without addressing the underlying sleep fragmentation is physiologically incomplete" [16].

Thyroid Hormone and Sleep Quality

Hypothyroidism and OSA frequently coexist. Uncontrolled hypothyroidism increases upper airway collapsibility by promoting mucopolysaccharide deposition in pharyngeal tissues [17]. The practical implication: a patient on levothyroxine whose TSH is within range but whose PSG still shows moderate OSA should not have their thyroid dose increased to "fix" the apnea. These are parallel problems requiring parallel treatment.

Conversely, a patient newly diagnosed with OSA whose TSH has never been checked should have labs drawn. The AACE/ACE guidelines recommend TSH screening when OSA is diagnosed alongside fatigue, weight gain, or cold intolerance [18].

GLP-1 Receptor Agonists and Sleep Study Outcomes

The intersection of GLP-1 medications and sleep apnea is one of the fastest-moving areas in treatment. Weight loss alone improves AHI. GLP-1 agonists produce weight loss. The question is whether the effect is large enough to change prescriptions.

SURMOUNT-OSA: The Landmark Data

The SURMOUNT-OSA trial, published in the New England Journal of Medicine in June 2024, randomized 469 adults with moderate-to-severe OSA and obesity to tirzepatide or placebo [5]. At 52 weeks, tirzepatide reduced AHI by 25.3 events/hour (vs. 5.3 for placebo) in participants not using CPAP. Nearly 43% of tirzepatide-treated patients achieved an AHI below 5, meaning they no longer met diagnostic criteria for OSA. Mean weight loss was 18.1%.

What This Means for Your Prescription

If you are already on a GLP-1 for weight loss or type 2 diabetes and your follow-up sleep study shows AHI below 5, your clinician may trial discontinuation of CPAP with periodic monitoring. This decision should not be made on a single night's data. The AASM recommends repeat testing after sustained weight loss of ≥10% to confirm durable AHI improvement [1].

For patients starting a GLP-1 who have not yet had a sleep study, baseline PSG provides a reference point. If the pre-treatment AHI is 20 and it drops to 4 after 9 months on semaglutide, the clinical significance is clear and documented.

Home Sleep Tests vs. In-Lab Polysomnography

Not every patient needs a full in-lab PSG. The AASM endorses home sleep apnea testing (HSAT) for uncomplicated adult patients with high pretest probability of moderate-to-severe OSA [19]. HSAT devices typically measure airflow, respiratory effort, and SpO2, but do not record EEG. That means they cannot assess sleep architecture.

When You Need the Full Lab Study

A full PSG is required when the clinician needs sleep architecture data (suspected narcolepsy, parasomnias, or periodic limb movement disorder), when the patient has significant cardiopulmonary disease, or when an initial HSAT is negative but clinical suspicion remains high. For HealthRX patients on TRT or GH peptides, the full PSG offers more clinically useful data because N3 and REM percentages directly inform hormone-therapy decisions.

Cost and Access Considerations

In-lab PSG costs $1,000 to $3,000 before insurance. Most commercial plans and Medicare cover diagnostic PSG with a physician order. HSAT devices cost $150 to $500 and can be shipped to the patient's home. The tradeoff is precision for convenience.

Retesting: When to Repeat Your Sleep Study

A single sleep study is a snapshot. Body weight, medication changes, and aging all shift AHI over time. Repeat testing is indicated after significant weight change (≥10%), initiation of TRT, CPAP pressure adjustments, or surgical intervention. The AASM does not mandate a fixed retest interval, but many sleep centers recommend every 2 to 5 years for stable patients and within 3 to 6 months after a treatment change [1].

Post-TRT Monitoring

For men starting testosterone, a follow-up PSG or HSAT at 3 to 6 months catches early worsening. If the AHI rises by more than 10 events/hour, the clinician should reassess the TRT dose, add or adjust CPAP, or consider switching from injectable testosterone to a transdermal formulation (which produces lower peak serum levels and may exert less effect on upper airway collapsibility) [13].

Post-GLP-1 Weight Loss Monitoring

After sustained weight loss on a GLP-1, repeat PSG can confirm whether CPAP can be deprescribed. The sleep study also captures any improvement in sleep architecture. Increased N3 percentage after weight loss has been documented in the Sleep AHEAD cohort and correlates with improved insulin sensitivity independent of BMI change [20].

Interpreting Your Report: Key Numbers at a Glance

| Metric | Normal Range | Clinical Action Threshold | |---|---|---| | AHI | <5 events/hr | ≥5 triggers diagnosis; ≥15 typically requires CPAP | | ODI (3%) | <5 events/hr | ≥15 associated with cardiovascular risk | | Oxygen nadir | ≥90% SpO2 | <80% prompts urgent treatment | | Sleep efficiency | ≥85% | <75% suggests significant sleep fragmentation | | N3 (deep sleep) | 13 to 23% TST | <10% may indicate blunted GH secretion | | REM | 20 to 25% TST | <15% may reflect medication effects or depression | | PLMI | <15/hr | ≥15 may warrant dopamine agonist or iron studies |

A board-certified sleep medicine physician should interpret your PSG in the context of your full medical history. Raw numbers without clinical context lead to over-treatment and under-treatment at equal rates.